Percheron Therapeutics Limited

ASX:PER Stock Report

Market Cap: AU$7.4m

Percheron Therapeutics Future Growth

Future criteria checks 5/6

Percheron Therapeutics is forecast to grow earnings and revenue by 24.7% and 42.1% per annum respectively. EPS is expected to grow by 35.8% per annum. Return on equity is forecast to be -144.1% in 3 years.

Key information

24.7%

Earnings growth rate

35.8%

EPS growth rate

Pharmaceuticals earnings growth36.9%
Revenue growth rate42.1%
Future return on equity-144.1%
Analyst coverage

Low

Last updated18 Dec 2024

Recent future growth updates

Recent updates

We Think Percheron Therapeutics (ASX:PER) Needs To Drive Business Growth Carefully

Jun 03
We Think Percheron Therapeutics (ASX:PER) Needs To Drive Business Growth Carefully

We Think Antisense Therapeutics (ASX:ANP) Needs To Drive Business Growth Carefully

Nov 13
We Think Antisense Therapeutics (ASX:ANP) Needs To Drive Business Growth Carefully

We're Not Very Worried About Antisense Therapeutics' (ASX:ANP) Cash Burn Rate

Jun 08
We're Not Very Worried About Antisense Therapeutics' (ASX:ANP) Cash Burn Rate

We Think Antisense Therapeutics (ASX:ANP) Can Afford To Drive Business Growth

Feb 14
We Think Antisense Therapeutics (ASX:ANP) Can Afford To Drive Business Growth

We're Hopeful That Antisense Therapeutics (ASX:ANP) Will Use Its Cash Wisely

Aug 26
We're Hopeful That Antisense Therapeutics (ASX:ANP) Will Use Its Cash Wisely

Here's Why We're Not Too Worried About Antisense Therapeutics' (ASX:ANP) Cash Burn Situation

May 12
Here's Why We're Not Too Worried About Antisense Therapeutics' (ASX:ANP) Cash Burn Situation

We Think Antisense Therapeutics (ASX:ANP) Needs To Drive Business Growth Carefully

Dec 23
We Think Antisense Therapeutics (ASX:ANP) Needs To Drive Business Growth Carefully

Here's Why We're Not Too Worried About Antisense Therapeutics' (ASX:ANP) Cash Burn Situation

Jun 24
Here's Why We're Not Too Worried About Antisense Therapeutics' (ASX:ANP) Cash Burn Situation

We Think Antisense Therapeutics (ASX:ANP) Can Afford To Drive Business Growth

Mar 11
We Think Antisense Therapeutics (ASX:ANP) Can Afford To Drive Business Growth

Will Antisense Therapeutics (ASX:ANP) Spend Its Cash Wisely?

Nov 26
Will Antisense Therapeutics (ASX:ANP) Spend Its Cash Wisely?

Earnings and Revenue Growth Forecasts

ASX:PER - Analysts future estimates and past financials data (AUD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
6/30/202772-20-203
6/30/20261-20-13-133
6/30/20251-23-16-163
6/30/20243-12-10-10N/A
3/31/20243-11-10-10N/A
12/31/20232-11-10-10N/A
9/30/20232-11-9-9N/A
6/30/20232-11-8-8N/A
3/31/20232-10-7-7N/A
12/31/20222-8-7-7N/A
9/30/20222-7-7-7N/A
6/30/20222-6-8-8N/A
3/31/20221-7-8-8N/A
12/31/20211-9-8-8N/A
9/30/20211-9-7-7N/A
6/30/20211-8-6-6N/A
3/31/20211-6-5-5N/A
12/31/20201-4-4-4N/A
9/30/20201-5-4-4N/A
6/30/20201-6-4-4N/A
3/31/20201-6-3-3N/A
12/31/20191-6-3-3N/A
9/30/20191-4-3-3N/A
6/30/20191-3-3-3N/A
3/31/20190-3-3-3N/A
12/31/20180-3-3-3N/A
9/30/20180-3-3-3N/A
6/30/20180-2-2-2N/A
3/31/20180-2N/A-2N/A
12/31/20170-2N/A-3N/A
9/30/20171-3N/A-3N/A
6/30/20171-3N/A-3N/A
3/31/20171-2N/A-2N/A
12/31/20161-2N/A-2N/A
9/30/20162-2N/A-2N/A
6/30/20162-3N/A-2N/A
3/31/20163-1N/A-1N/A
12/31/201541N/A0N/A
9/30/201551N/A1N/A
6/30/201551N/A1N/A
3/31/20153-1N/A-1N/A
12/31/20141-3N/A-3N/A
9/30/20141-3N/A-3N/A
6/30/20141-3N/A-3N/A
3/31/20141-3N/A-2N/A
12/31/20131-3N/A-2N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: PER is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.6%).

Earnings vs Market: PER is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: PER is expected to become profitable in the next 3 years.

Revenue vs Market: PER's revenue (42.1% per year) is forecast to grow faster than the Australian market (5.8% per year).

High Growth Revenue: PER's revenue (42.1% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: PER is forecast to be unprofitable in 3 years.

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/22 06:56
End of Day Share Price 2024/12/20 00:00
Earnings2024/06/30
Annual Earnings2024/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Percheron Therapeutics Limited is covered by 4 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
John HesterBell Potter
Iain WilkieMorgans Financial Limited
Dr StoreyWilsons Advisory and Stockbroking Ltd.